{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:50Z","timestamp":1790346710157,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Fundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymthe.2024.06.029","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T22:33:18Z","timestamp":1719095598000},"page":"3114-3127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Overcoming effector T\u00a0cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine"],"prefix":"10.1016","volume":"32","author":[{"given":"Saru","family":"Basnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirte","family":"Van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne C.A.","family":"Quixabeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Jirovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna A.M.","family":"Gr\u00f6nberg-V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.A.","family":"Clubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santeri","family":"Pakola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyna","family":"Haybout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kudling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-8530","authenticated-orcid":false,"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.06.029_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2024.06.029_bib2","doi-asserted-by":"crossref","first-page":"e003490","DOI":"10.1136\/jitc-2021-003490","article-title":"Oncolytic adenovirus decreases the proportion of TIM-3\u00a0+ subset of tumor-infiltrating CD8\u00a0+ T\u00a0cells with correlation to improved survival in patients with cancer","volume":"10","author":"Liikanen","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.06.029_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.omto.2022.12.007","article-title":"Oncolytic adenovirus coding for bispecific T\u00a0cell engager against human MUC-1 potentiates T\u00a0cell response against solid tumors","volume":"28","author":"Basnet","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2024.06.029_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/14760584.4.4.493","article-title":"MUC1 as a target antigen for cancer immunotherapy","volume":"4","author":"Acres","year":"2005","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2024.06.029_bib5","first-page":"801","article-title":"Overexpression of MUC1 predicts poor prognosis in patients with breast cancer","volume":"41","author":"Jing","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ymthe.2024.06.029_bib6","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms22126567","article-title":"Muc1: Structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.06.029_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/mco.2022.2594","article-title":"Expression of MUC1 in different tumours and its clinical significance (Review)","volume":"17","author":"Lan","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1089\/hum.2023.099","article-title":"Viral vectors expressing interleukin 2 for cancer immunotherapy","volume":"34","author":"Wang","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.029_bib9","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The First Effective Immunotherapy for Human Cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/biomedicines8070204","article-title":"Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy","volume":"8","author":"Guo","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2024.06.029_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5493\/wjem.v5.i1.11","article-title":"Internal ribosome entry site-based vectors for combined gene therapy","volume":"5","author":"Renaud-Gabardos","year":"2015","journal-title":"World J. Exp. Med."},{"key":"10.1016\/j.ymthe.2024.06.029_bib13","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2024.06.029_bib14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.06.029_bib15","doi-asserted-by":"crossref","first-page":"794251","DOI":"10.3389\/fimmu.2022.794251","article-title":"Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer","volume":"13","author":"Clubb","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10555-013-9423-y","article-title":"The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression","volume":"32","author":"Deng","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2024.06.029_bib17","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","article-title":"Selective recruitment of \u03b3\u03b4 T\u00a0cells by a bispecific antibody for the treatment of acute myeloid leukemia","volume":"35","author":"Ganesan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.06.029_bib18","doi-asserted-by":"crossref","first-page":"eabb0192","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites- And tumor-infiltrating \u03b3\u03b4 T\u00a0cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.06.029_bib19","doi-asserted-by":"crossref","first-page":"2096572","DOI":"10.1080\/2162402X.2022.2096572","article-title":"Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression","volume":"11","author":"Kudling","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.06.029_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/cells10020246","article-title":"Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor anti-PD-1","volume":"10","author":"Havunen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.06.029_bib21","doi-asserted-by":"crossref","first-page":"E4978","DOI":"10.1073\/pnas.1315370110","article-title":"Ascites analysis by a microfluidic chip allows tumor-cell profiling","volume":"110","author":"Peterson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.06.029_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-4939-9794-7_17","article-title":"Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity","volume":"2058","author":"Scott","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2161-0932.1000396","article-title":"Characterization of Immunosuppressive Properties of Malignant Ascites in Ovarian Carcinoma","volume":"6","author":"Bains","year":"2016","journal-title":"Gynecol. Obstet."},{"key":"10.1016\/j.ymthe.2024.06.029_bib24","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3389\/fimmu.2018.03156","article-title":"Survival of ovarian cancer patients is independent of the presence of DC and T\u00a0cell subsets in ascites","volume":"10","author":"Wefers","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib25","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/biomedicines10112826","article-title":"The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer","volume":"10","author":"Koz\u0142owski","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2024.06.029_bib26","doi-asserted-by":"crossref","first-page":"156412","DOI":"10.1016\/j.cyto.2023.156412","article-title":"BTLA and HVEM: Emerging players in the tumor microenvironment and cancer progression","volume":"172","author":"Mohamed","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.ymthe.2024.06.029_bib27","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1111\/cas.15167","article-title":"The prognostic value of TCF1+CD8+T in primary small cell carcinoma of the esophagus","volume":"112","author":"Ma","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ymthe.2024.06.029_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcell.2020.00017","article-title":"T Cell Dysfunction and Exhaustion in Cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.37349\/ei.2022.00054","article-title":"Allogeneic gamma delta T\u00a0cells as adoptive cellular therapy for hematologic malignancies","volume":"2","author":"Jhita","year":"2022","journal-title":"Explor. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib30","doi-asserted-by":"crossref","first-page":"e0191024","DOI":"10.1371\/journal.pone.0191024","article-title":"Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.06.029_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fgene.2018.00650","article-title":"Apolipoprotein E Overexpression Is Associated With Tumor Progression and Poor Survival in Colorectal Cancer","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymthe.2024.06.029_bib32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1046\/j.1365-2567.2002.01523.x","article-title":"Down-regulation of the myeloid homeobox protein Hex is essential for normal T-cell development","volume":"107","author":"Mack","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2024.06.029_bib33","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.3892\/ijo.2016.3740","article-title":"Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K\/Akt pathway","volume":"49","author":"Zhang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.029_bib34","doi-asserted-by":"crossref","first-page":"10346","DOI":"10.1038\/ncomms10346","article-title":"C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation","volume":"7","author":"Bulla","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.029_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites-and tumor-infiltrating \u03b3\u03b4 T\u00a0cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.06.029_bib36","series-title":"Targeting Resident Memory T Cells for Cancer Immunotherapy","author":"Blanc","year":"2018"},{"key":"10.1016\/j.ymthe.2024.06.029_bib37","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/cells9040798","article-title":"TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling","volume":"9","author":"Heini\u00f6","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.06.029_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/hum.2020.222","article-title":"Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples","volume":"32","author":"Zafar","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.029_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Kanerva","year":"2003","journal-title":"Mol. Ther."}],"updated-by":[{"DOI":"10.1016\/j.ymthe.2024.07.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000}}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400412X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400412X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:48:15Z","timestamp":1728305295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162400412X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S152500162400412X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.029","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ymthe.2024.07.009","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming effector T\u00a0cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}